TOP1 and neoplasm: Indeed, in a phase I/II SG basket trial (NCT01631552), of 9 patients that had previously failed therapies consisting of TOP1 inhibitors, 2 demonstrated significant tumor regressions of target lesions after SG treatment, 5 had stable disease, while the remaining 2 patients progressed during treatment [49].